07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Chaperoning the DJ

  In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the neurotransmitter with a strategy to block the protein misfolding and oxidative damage that drive neurodegeneration in...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Company News

Cantabio, Purdue University deal

Cantabio and the university’s Purdue Research Foundation partnered to evaluate small molecule chaperone candidates from the biotech that target DJ-1 (PARK7) to treat neurodegenerative diseases, including Parkinson’s disease (PD). Cantabio will have access to resulting...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Cantabio, University of Antioquia deal

Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partners are focusing on protective effects of Cantabio’s candidates and cellular...
07:00 , Aug 6, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DJ-1 (PARK7)

Endocrine/metabolic disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting DJ-1 could help treat obesity. In mice, a high-fat diet increased muscle levels of DJ-1 mRNA compared with a normal diet. In cultured mouse...
07:00 , Sep 27, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Dj-1 (Park7)-deficient mice as models for Parkinson's disease (PD)-associated neurodegeneration Dj-1-deficient mice could be useful models for PD. The Dj-1-deficient animals were generated by backcrossing...
07:00 , Jun 30, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Toxoplasma gondii DJ-1 In vitro studies identified a covalent modifier of the T. gondii DJ-1 protein that could help treat parasite infection....
07:00 , Oct 22, 2009 |  BC Innovations  |  Cover Story

Rat race in PD

The Michael J. Fox Foundation for Parkinson's Research...
08:00 , Mar 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Parkinson disease (autosomal recessive, juvenile) 2 parkin (PARK2; Parkin); PTEN induced putative kinase 1 (PINK1); DJ-1 (PARK7);...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer DJ-1 (PARK7); hypoxia-inducible factor 1a (HIF1a) Studies in cell culture suggest that inhibiting DJ-1 signaling may be useful for treating...